PL2717898T3 - Związki o działaniu prokoagulacyjnym i sposoby ich stosowania - Google Patents

Związki o działaniu prokoagulacyjnym i sposoby ich stosowania

Info

Publication number
PL2717898T3
PL2717898T3 PL12797036T PL12797036T PL2717898T3 PL 2717898 T3 PL2717898 T3 PL 2717898T3 PL 12797036 T PL12797036 T PL 12797036T PL 12797036 T PL12797036 T PL 12797036T PL 2717898 T3 PL2717898 T3 PL 2717898T3
Authority
PL
Poland
Prior art keywords
pro
methods
coagulant compounds
coagulant
compounds
Prior art date
Application number
PL12797036T
Other languages
English (en)
Inventor
Karina THORN
Garabet G. TOBY
Adam R. Mezo
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of PL2717898T3 publication Critical patent/PL2717898T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicinal Preparation (AREA)
PL12797036T 2011-06-10 2012-06-09 Związki o działaniu prokoagulacyjnym i sposoby ich stosowania PL2717898T3 (pl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161495818P 2011-06-10 2011-06-10
US201161496542P 2011-06-13 2011-06-13
US201161496541P 2011-06-13 2011-06-13
US201161496540P 2011-06-13 2011-06-13
US201161496543P 2011-06-13 2011-06-13
US201261600237P 2012-02-17 2012-02-17
US201261605540P 2012-03-01 2012-03-01
EP12797036.6A EP2717898B1 (en) 2011-06-10 2012-06-09 Pro-coagulant compounds and methods of use thereof
PCT/US2012/041777 WO2012170969A2 (en) 2011-06-10 2012-06-09 Pro-coagulant compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2717898T3 true PL2717898T3 (pl) 2019-06-28

Family

ID=47296790

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12797036T PL2717898T3 (pl) 2011-06-10 2012-06-09 Związki o działaniu prokoagulacyjnym i sposoby ich stosowania

Country Status (14)

Country Link
US (1) US9486507B2 (pl)
EP (2) EP3527218A1 (pl)
AU (1) AU2012267484B2 (pl)
CA (1) CA2838833A1 (pl)
CY (1) CY1121509T1 (pl)
DK (1) DK2717898T3 (pl)
ES (1) ES2724778T3 (pl)
HR (1) HRP20190494T1 (pl)
HU (1) HUE043894T2 (pl)
LT (1) LT2717898T (pl)
PL (1) PL2717898T3 (pl)
PT (1) PT2717898T (pl)
SI (1) SI2717898T1 (pl)
WO (1) WO2012170969A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803730A1 (en) * 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
WO2013185113A1 (en) * 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
CN104427995A (zh) 2012-06-08 2015-03-18 比奥根艾迪克Ma公司 嵌合凝血因子
HK1220910A1 (zh) 2013-05-24 2017-05-19 Biogen Ma Inc. 抗-gpiib/iiia抗體或其用途
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US20190307879A1 (en) * 2015-12-04 2019-10-10 The Texas A&M University System Adenovirus-vectored multivalent vaccine
US10557160B2 (en) 2015-12-15 2020-02-11 Board Of Regents, The University Of Texas System Transgenic bacteria with expanded amino acid usage and nucleic acid molecules for use in the same
CA3018691C (en) 2016-04-06 2021-11-30 Alteogen, Inc. Antibody-drug conjugates comprising antibodies modified with metal ion-binding motifs
WO2017176007A1 (ko) * 2016-04-06 2017-10-12 (주)알테오젠 변형항체를 포함하는 항체-약물 접합체
US11155804B2 (en) 2016-07-11 2021-10-26 Board Of Regents, The University Of Texas System Recombinant polypeptides comprising selenocysteine and method for producing the same
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN109803679A (zh) 2016-08-30 2019-05-24 得克萨斯州大学系统董事会 在基因组重新编码生物体中生产硒代生物制剂
WO2018102317A1 (en) * 2016-11-29 2018-06-07 The Regents Of The University Of California Modulation of p53 for the treatment of cancer
KR20260008164A (ko) * 2016-12-02 2026-01-15 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
US11519917B2 (en) 2017-04-13 2022-12-06 The Regents Of The University Of Michigan Assay for quantifying polyphosphates
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
CN113164560A (zh) * 2018-10-26 2021-07-23 Vrije布鲁塞尔大学 改善基因疗法的新工具及其用途
CN109507966A (zh) * 2018-11-20 2019-03-22 东华大学 一种面向纬编面料生产的智能管控系统
CN113101413B (zh) * 2020-01-13 2022-04-08 中国科学院苏州纳米技术与纳米仿生研究所 有序水凝胶纤维支架、其制备方法及应用

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
DE3751908T2 (de) 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
CA1339445C (en) 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8704647D0 (en) * 1987-02-27 1987-04-01 Guy S & St Thomas S Hospitals Vaccine
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2053864C (en) 1989-02-21 2001-11-20 Irving Boime Modified forms of reproductive hormones
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1994018954A1 (en) 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
US5972674A (en) 1996-08-26 1999-10-26 Signal Pharmaceuticals, Inc. Stimulus-inducible protein kinase complex and methods of use therefor
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9723062D0 (en) * 1997-10-31 1998-01-07 Cambridge Antibody Tech Improvements relating to antibodies and libraries thereof
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU781618C (en) 1999-07-02 2006-03-16 Genentech Inc. FVIIa antagonists
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
PT2275552E (pt) * 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
CN100488562C (zh) 2000-02-11 2009-05-20 拜耳医药保健有限公司 凝血因子VⅡ或VⅡa样分子
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
ATE485371T1 (de) 2000-05-03 2010-11-15 Novo Nordisk Healthcare Ag Varianten des menschlichen koagulationsfaktors vii
EP1335931B1 (en) 2000-05-16 2005-12-21 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US6888319B2 (en) 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
JP2004529640A (ja) 2001-03-22 2004-09-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ凝固因子誘導体
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040254106A1 (en) 2001-09-04 2004-12-16 Carr Francis J. Modified factor ix
AU2002333211B2 (en) 2001-09-27 2008-05-08 Novo Nordisk Health Care Ag Human coagulation factor VII polypeptides
EP1300419B1 (en) 2001-10-05 2007-06-13 Affimed Therapeutics AG Antibody of human origin for inhibiting thrombocyte aggregation
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
IL162604A0 (en) * 2002-01-03 2005-11-20 Yissum Res Dev Co Conformationally constrained c-backbone cyclic peptides
EP1339006A1 (en) * 2002-02-14 2003-08-27 AgeLab Pharma GmbH Method for the detection of a functional protein sequence and an apparatus therefor
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20030170850A1 (en) * 2002-03-09 2003-09-11 Cardone Michael H. Cell-based screening methods
CN101143221A (zh) 2002-03-15 2008-03-19 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
MXPA04010781A (es) 2002-04-30 2005-03-07 Maxygen Holdings Ltd Variantes de polipeptido del factor vii o viia.
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
DE60330923D1 (de) 2002-09-25 2010-02-25 Novo Nordisk Healthcare Ag Menschliche Koagulationsfaktor VII Polypeptide
SI2345671T1 (sl) 2002-09-27 2016-03-31 Xencor Inc. Optimizirane Fc-variante in postopki za njihovo izdelavo
WO2004035752A2 (en) 2002-10-15 2004-04-29 Protein Design Labs, Inc. ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2004085633A1 (en) 2003-03-24 2004-10-07 The University Of Hong Kong A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc. Optimized Fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
US20100056392A1 (en) * 2005-06-15 2010-03-04 Matthew Greving Microstructure and microdomain microarrays, methods of making same and uses thereof
EP1893631B1 (en) 2005-06-17 2013-08-14 Novo Nordisk Health Care AG Dimeric and multimeric fviia compounds
EP1924596A4 (en) 2005-08-12 2009-07-29 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2007203960A1 (en) 2006-01-04 2007-07-12 Do-Coop Technologies Ltd. Antiseptic compositions and methods of using same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
CN101406105B (zh) 2006-03-13 2010-11-10 皇家飞利浦电子股份有限公司 用于固态照明系统的自适应控制装置和方法
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
KR20090064453A (ko) 2006-09-14 2009-06-18 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
JP2008289374A (ja) * 2007-05-22 2008-12-04 Kyushu Univ タンパク質キナーゼの新規基質ポリペプチド
US20090131306A1 (en) * 2007-06-15 2009-05-21 Adherex Technologies, Inc. Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CN102065887A (zh) 2008-04-16 2011-05-18 拜耳医药保健有限公司 因子ix的定点修饰
AU2009244633A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified Factor IX polypeptides and uses thereof
AR071478A1 (es) 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
US20090305297A1 (en) * 2008-06-06 2009-12-10 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2347263B1 (en) * 2008-10-03 2017-05-17 President and Fellows of Harvard College Methods, compositions and kits for high throughput kinase activity screening using mass spectrometry and stable isotopes
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
NZ621868A (en) 2009-06-08 2015-10-30 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
DK2440228T3 (en) 2009-06-08 2018-12-17 Amunix Operating Inc Glucose regulating polypeptides and methods for their preparation and use
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
SG181130A1 (en) 2009-12-06 2012-07-30 Biogen Idec Hemophilia Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
CA2800535A1 (en) 2010-05-24 2011-12-01 Phosimmune, Inc. Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CN104427995A (zh) * 2012-06-08 2015-03-18 比奥根艾迪克Ma公司 嵌合凝血因子
WO2013185113A1 (en) * 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds

Also Published As

Publication number Publication date
NZ619079A (en) 2016-11-25
US20140303084A1 (en) 2014-10-09
ES2724778T3 (es) 2019-09-16
WO2012170969A3 (en) 2013-08-15
HUE043894T2 (hu) 2019-09-30
CA2838833A1 (en) 2012-12-13
EP3527218A1 (en) 2019-08-21
HRP20190494T1 (hr) 2019-07-12
WO2012170969A2 (en) 2012-12-13
EP2717898B1 (en) 2018-12-19
SI2717898T1 (sl) 2019-07-31
US9486507B2 (en) 2016-11-08
AU2012267484B2 (en) 2017-03-23
PT2717898T (pt) 2019-05-20
EP2717898A4 (en) 2014-11-26
EP2717898A2 (en) 2014-04-16
LT2717898T (lt) 2019-03-25
DK2717898T3 (en) 2019-03-25
AU2012267484A1 (en) 2014-01-16
CY1121509T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
SI2717898T1 (sl) Spojine prokoagulantov in metode za njihovo uporabo
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
ZA201303793B (en) Substituted quinoline compounds and methods of use
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
ZA201405248B (en) Anesthetic compounds and related methods of use
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
SG11201504049VA (en) Compounds and their methods of use
IL232055B (en) Anti-1htra antibodies and methods of use
GB201111705D0 (en) Compounds and their use
IL228072A0 (en) Alkyl-substituted quinazoline compounds and methods of use
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
GB201114448D0 (en) Compounds and their use
PL2736328T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
PL2736339T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
GB201104632D0 (en) Use of medicament
GB201104875D0 (en) New compounds and medical uses
GB201104872D0 (en) New compounds and medical uses
AU2011903137A0 (en) Compounds and methods of their use - IV
GB201109737D0 (en) Methods of treatment
GB201110602D0 (en) Methods of treatment
GB201104444D0 (en) Compounds and their use